Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Boilerplate Regulation FD disclaimer only; no substantive investor information disclosed.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer only; no substantive investor information disclosed
- No new financial, clinical, operational, or corporate development details in the provided text
Item 8.01 · Other Events
- TNX-1500 Phase 1 study enrolled 26 healthy adults across 3, 10, and 30 mg/kg dose cohorts
- Primary T-cell antibody response blocked at all doses, supporting proof-of-mechanism for immune suppression
- Secondary response blocked at 10 and 30 mg/kg; 3 mg/kg reduced peak response approximately 70% versus placebo
- Findings support development for transplant rejection prevention and autoimmune diseases
- Early-stage, single-center safety and efficacy evidence remains subject to later clinical and regulatory validation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.